Patient-Centered Outcomes; Real-World Evidence & Data Analytics
Bethesda, United States
Sophie Tsai is an Associate Scientist in Patient-Centered Outcomes and Real-World Evidence & Data Analytics, located in Pharmerit’s Bethesda, MD office. Her expertise includes patient preferences, patient-reported outcomes, rare-diseases, patient-engagement, patient-advocacy group (PAG) engagement, and patient-focused drug development (PFDD). Sophie has therapeutic experience in the following areas: pediatric diseases, rare diseases, neurodevelopmental diseases, multi-system genetic disorders.
Previously, Sophie worked as a post-doctoral fellow within the Center for Health Services and Outcomes Research (CHSOR) in the Department of Health Policy and Management at the Johns Hopkins Bloomberg School of Public Health. Her research focuses on applying stated-preference methods to prioritize clinical outcomes associated with the disease and preferences for the benefits and risks of treatments.
She introduced a novel patient advocacy group engagement method in her manuscript titled, “Research as an Event: a Novel Approach to Promote Patient-focused Drug Development,” documenting a resource-efficient method to partner with PAGs and engage patients and caregivers in research. She has partnered with patient advocacy groups (such as Parent Project Muscular Dystrophy and the Foundation for Prader-Willi Research) and engaged the disease community as partners in research. She has also served as the Team Leader of the Johns Hopkins stated-preference research team at an FDA public workshop to determine patient and FDA reviewer priorities in prosthetic devices. Sophie obtained a Medical Doctor degree from Taipei Medical University in 2013 and a Masters in Health Science in Health Economics degree at Johns Hopkins in 2016 where she was inducted into Delta Omega, the schools honors society.